Shots:
- Sandoz agreed to acquire Just-Evotec Biologics EU SAS in Toulouse , including its manufacturing site to expand in-house continuous manufacturing for biosimilars, supporting its strategy to capture a projected ~$300B biosimilars market over the next decade
- Sandoz will buy 100% of Just-Evotec Biologics SAS and secure a perpetual license for its continuous manufacturing platform for ~$350M upfront. The deal includes royalties on up to 10 molecules, restructures the partnership, aligning incentives via license fees and development costs, with potential milestones of ~$300M
- The investment fits Sandoz’s current capital plans and does not affect its 2025 guidance
Ref: Sandoz | Image: Just-Evotec Biologics | Press Release
Related News:- Alvotech Provides Update on BLA of AVT05 (Biosimilar, Simponi)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
